VMD-928
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
What's the purpose of the trial?
Accepting patients
Participating Centers
There are 7 centers participating in this trial. Enter a location below to find the closet center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- VMD-928 is a TrkA (NTRK1) selective inhibitor currently in development.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.